Pharmceutcial Material CAS 763113-22-0 Olaparib for Breast Cancer Treatment

Model NO.: 763113-22-0
Appearance: White Crystalline Powder
Usage: Building Muscle, Burning Fat and Gaining Strength
Payment: Western Union, Moneygram, T/T
Delivery: 3-5 Days 100%Door to Door
Export Markets: Global
Shipment: EMS, FedEx, TNT, DHL, UPS
Trademark: CJC
Transport Package: 1kg/Aluminum Foil Bag
Specification: USP/BP
Origin: China
HS Code: 3913900000
Model NO.: 763113-22-0
Appearance: White Crystalline Powder
Usage: Building Muscle, Burning Fat and Gaining Strength
Payment: Western Union, Moneygram, T/T
Delivery: 3-5 Days 100%Door to Door
Export Markets: Global
Shipment: EMS, FedEx, TNT, DHL, UPS
Trademark: CJC
Transport Package: 1kg/Aluminum Foil Bag
Specification: USP/BP
Origin: China
HS Code: 3913900000
Pharmceutcial Material CAS 763113-22-0 Olaparib for Breast Cancer Treatment

Olaparib 


Therapeutic agent of ovarian cancer Pharmacological effects Pharmacokinetics Drug Interactions Side effects

Product Name:    Olaparib

Synonyms:    4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]Methyl]-1(2H)-phthalazinone;KU 59436;AZD2281(olaparib)/AZD-2281;1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin;Olaparid AZD2281;Olaparib (AZD2281, Ku-0059436);Olaparid

CAS:    763113-22-0

MF:    C24H23FN4O3

MW:    434.469

Product Categories:    Inhibitor;Inhibitors;APIs;API

Mol File:    763113-22-0.mol



Olaparib Specification COA 
 

Product name
 Olapari
CAS
CAS No.

763113-22-0

Outer Packing

100G

Production date

2017.11.16

Shelf life

2019.11.15

Standard adopted
Enterprise Standard 

Items of analysis

Specification

Results
Appearanc White powde Confor
Purit
≥99.5%

99.71%
The largest single hybri
≤0.1%

0.08%
Total Hybr
≤0.5%

0.29%
Ethano
≤0.5%

0.097%
Acetic aci
≤0.5%

0.003%
Dioxan
≤0.5%

NA
Wate
≤0.5%
Confor

Conclusion

Qualified



Olaparib Delayed product: Orapanib capsules

Olaparib Use: maintenance therapy for patients with recurrent severe ovarian cancer who are susceptible to mutations in the breast cancer susceptibility gene (BRCA) and are platinum-sensitive

Olaparib Dosage: For scientific research only


 

Related material 

Pharmceutcial Material CAS 763113-22-0 Olaparib for Breast Cancer Treatment


Pharmceutcial Material CAS 763113-22-0 Olaparib for Breast Cancer Treatment



Advantage : More than 11,000 material in stock . Any inquiry on pharmaceutical ,chemical etc, we can supply one time . Gurantee shipping within 3 hours ,promise 5-7 business days on delivery 

If you are need safe and fast way , we will be your best choice .Do not hesitate to contact us if you need :)

24 hours service online 

Contact Yolanda :)
Pharmceutcial Material CAS 763113-22-0 Olaparib for Breast Cancer Treatment

Olaparib 


Therapeutic agent of ovarian cancer Pharmacological effects Pharmacokinetics Drug Interactions Side effects

Product Name:    Olaparib

Synonyms:    4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]Methyl]-1(2H)-phthalazinone;KU 59436;AZD2281(olaparib)/AZD-2281;1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin;Olaparid AZD2281;Olaparib (AZD2281, Ku-0059436);Olaparid

CAS:    763113-22-0

MF:    C24H23FN4O3

MW:    434.469

Product Categories:    Inhibitor;Inhibitors;APIs;API

Mol File:    763113-22-0.mol



Olaparib Specification COA 
 

Product name
 Olapari
CAS
CAS No.

763113-22-0

Outer Packing

100G

Production date

2017.11.16

Shelf life

2019.11.15

Standard adopted
Enterprise Standard 

Items of analysis

Specification

Results
Appearanc White powde Confor
Purit
≥99.5%

99.71%
The largest single hybri
≤0.1%

0.08%
Total Hybr
≤0.5%

0.29%
Ethano
≤0.5%

0.097%
Acetic aci
≤0.5%

0.003%
Dioxan
≤0.5%

NA
Wate
≤0.5%
Confor

Conclusion

Qualified



Olaparib Delayed product: Orapanib capsules

Olaparib Use: maintenance therapy for patients with recurrent severe ovarian cancer who are susceptible to mutations in the breast cancer susceptibility gene (BRCA) and are platinum-sensitive

Olaparib Dosage: For scientific research only


 

Related material 

Pharmceutcial Material CAS 763113-22-0 Olaparib for Breast Cancer Treatment


Pharmceutcial Material CAS 763113-22-0 Olaparib for Breast Cancer Treatment



Advantage : More than 11,000 material in stock . Any inquiry on pharmaceutical ,chemical etc, we can supply one time . Gurantee shipping within 3 hours ,promise 5-7 business days on delivery 

If you are need safe and fast way , we will be your best choice .Do not hesitate to contact us if you need :)

24 hours service online 

Contact Yolanda :)